Autres langues CKD Corporation

Actions

6407

JP3346800000

Machines et équipements industriels

Marché Fermé - Japan Exchange 08:30:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
5 460,00 ^JPY	+2,06%		+7,06%	+78,43%

10/08	CKD Corporation révise ses prévisions de résultats consolidés pour l'exercice clos le 31 mars 2027	CI
10/08	CKD Corporation révise ses prévisions de dividendes pour l'exercice clos le 31 mars 2027	CI

Autres langues

10/08	CKD Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027
10/08	CKD Corporation Revises Dividend Guidance for the Fiscal Year Ending March 31, 2027
10/08	CKD Corporation Reports Earnings Results for the First Quarter Ended June 30, 2026
09/07	CKD Subsidiary Hit by 178 Million Yen Embezzlement; Former Employee Arrested
15/05	CKD Corporation Provides Consolidated Earnings Forecast for the Full Fiscal Year Ending March 31, 2027
15/05	CKD Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027
15/05	CKD Corporation Announces Board and Committee Retirements
15/05	Ckd Corporation Declares Dividend for the Fiscal Year Ending March 31, 2026, Payable on June 11, 2026
15/05	CKD Corporation Reports Earnings Results for the Full Year Ended March 31, 2026
01/04	Sprint Bioscience reports positive proof-of-concept results from program in CKD
28/03	Vivoryon Therapeutics N.V. Provides Update On Growing Body Of Evidence Validating Glutaminyl Cyclases As Promising Targets In DKD
16/03	Bayer says finerenone meets primary endpoint in investigational phase III FIND-CKD study
13/02	CKD Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025
10/12	Idorsia veröffentlicht weitere Studiendaten zu Bluthochdrucksenker Aprocitentan
14/11	CKD Corporation Announces Dividend for the End of Second Quarter of Fiscal Year Ending March 31, 2026, Payable on December 8, 2025; Revises Year End Dividend Guidance for the Fiscal Year Ending March 31, 2026
14/11	CKD Corporation Revises Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2026
10/11	Akebia Therapeutics Q3 revenue rises
08/11	Alnylam Pharmaceuticals, Inc. Announces Results from New Post Hoc Analysis of the Helios-B Phase 3 Study of Vutrisiran
07/11	HighTide Therapeutics Presents the Evidence of Kidney Benefit with HTD1801
03/11	Modus Therapeutics Holding AB Receives Regulatory Approval for Part 2 of the Phase IIa Study in CKD- with Anemia
06/10/25	Roche obtains CE marking for Kidney Klinrisk AI algorithm
06/10/25	Roche receives CE Mark for AI-based kidney Klinrisk algorithm
02/10/25	South Africa secures China, India investments to boost local auto manufacturing
17/09/25	Arch Biopartners Acquires Platform to Develop New Drugs Targeting Chronic Kidney Disease
21/08/25	Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® Across All IRC Dialysis Clinics